Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARCT-2303
- Development stage
- Phase 3
- Lead developer
- CSL Seqirus
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ARCT-2303 is a monovalent self-amplifying mRNA vaccine developed by Arcturus Therapeutics, in collaboration with CSL, for the prevention of COVID-19. It is designed to stimulate an immune response against SARS-CoV-2 by delivering mRNA encoding viral antigens, leading to the production of protective proteins that trigger immunostimulation. The vaccine has demonstrated superior immune responses compared to earlier candidates (such as ARCT-154), particularly in generating neutralizing antibodies against Omicron variants like XBB.1.5. As of late 2024, ARCT-2303 has completed Phase III clinical trials for COVID-19 prevention in multiple countries including Costa Rica, Honduras, Philippines, and Australia[2][4][5].
- Other names
- ARCT 2303ARCT2303ARCT-2303
Beyond the preview
Go deeper on ARCT-2303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARCT-2303.